A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients

被引:9
|
作者
Bark, Juliana Muller [1 ,2 ,3 ]
Karpe, Avinash V. [4 ,5 ]
Doecke, James D. [6 ]
Leo, Paul [3 ,7 ]
Jeffree, Rosalind L. [8 ,9 ,10 ,11 ]
Chua, Benjamin [9 ,12 ]
Day, Bryan W. [3 ,9 ,11 ]
Beale, David J. [4 ]
Punyadeera, Chamindie [2 ,13 ,14 ,15 ]
机构
[1] Queensland Univ Technol, Fac Hlth, Ctr Biomed Technol, Sch Biomed Sci, Brisbane, Qld, Australia
[2] Griffith Univ, Griffith Inst Drug Discovery, Saliva & Liquid Biopsy Translat Lab, Brisbane, Qld, Australia
[3] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Gardens Point, Qld, Australia
[4] Environm Commonwealth Sci & Ind Res Org CSIRO, Ecosci Precinct, Dutton Pk, Qld, Australia
[5] Commonwealth Sci & Ind Res Org CSIRO, Agr & Food, Acton, ACT, Australia
[6] Royal Brisbane & Womens Hosp, Australian EHlth Res Ctr, Surg Treatment & Rehabil Serv STARS, CSIRO, Level 7, Herston, Qld, Australia
[7] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Translat Genom Grp, Woolloongabba, Australia
[8] QIMR Berghofer Med Res Inst, Herston, Qld, Australia
[9] Univ Queensland, Fac Med, Herston, Qld, Australia
[10] Royal Brisbane & Womens Hosp, Kenneth G Jamieson Dept Neurosurg, Brisbane, Qld, Australia
[11] QIMR Berghofer MRI, Cell & Mol Biol Dept, Sid Faithfull Brain Canc Lab, Brisbane, Qld, Australia
[12] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia
[13] Griffith Univ, Menzies Hlth Inst, Southport, Qld, Australia
[14] Translat Res Inst, Woolloongabba, Qld, Australia
[15] Griffith Inst Drug Discovery, Saliva & Liquid Biopsy Translat Lab, 46 Don Young Rd, Nathan, Qld 4111, Australia
来源
CANCER MEDICINE | 2023年 / 12卷 / 10期
基金
英国医学研究理事会;
关键词
blood; glioblastoma; lipids; metabolites; metabolomics; saliva; ARGININE DEPRIVATION; CANCER; BIOSYNTHESIS; GLYCOLYSIS; CHALLENGES; BIOMARKERS; PROTEIN; GROWTH; TUMORS; CELLS;
D O I
10.1002/cam4.5857
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients.Methods: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression-free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS <= 9 months, respectively). Analysis of saliva (whole-mouth and oral rinse) and plasma samples was conducted utilising LC-QqQ-MS and LC-QTOF-MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO-based graphic network analyses.Results: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic-AMP, 3-hydroxy-kynurenine, dihydroorotate, UDP and cis-aconitate were elevated, compared to patients with favourable outcomes during pre-and post-surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group.Conclusion: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.
引用
收藏
页码:11427 / 11437
页数:11
相关论文
共 50 条
  • [41] Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson's Disease: A Pilot Study
    Yilmaz, Ali
    Ugur, Zafer
    Ustun, Ilyas
    Akyol, Sumeyya
    Bahado-Singh, Ray O.
    Maddens, Michael
    Aasly, Jan O.
    Graham, Stewart F.
    CELLS, 2020, 9 (11)
  • [42] Profiling of plasma-derived exosomal RNA expression in patients with periodontitis: A pilot study
    Kwon, Eun Jung
    Kim, Hyun-Joo
    Woo, Bok Hee
    Joo, Ji-Young
    Kim, Yun Hak
    Park, Hae Ryoun
    ORAL DISEASES, 2023, 29 (04) : 1726 - 1737
  • [43] Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
    Seidel, Clemens
    Doerner, Nils
    Osswald, Matthias
    Wick, Antje
    Platten, Michael
    Bendszus, Martin
    Wick, Wolfgang
    BMC CANCER, 2011, 11
  • [44] Proteomic analysis of plasma samples from acute coronary syndrome patients - The pilot study
    Maly, Martin A.
    Majek, Pavel
    Reicheltova, Zuzana
    Kotlin, Roman
    Suttnar, Jiri
    Oravec, Milan
    Veselka, Josef
    Dyr, Jan E.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 157 (01) : 126 - 128
  • [45] NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
    Sim, Hao-Wen
    Wachsmuth, Luke
    Barnes, Elizabeth H.
    Yip, Sonia
    Koh, Eng-Siew
    Hall, Merryn
    Jennens, Ross
    Ashley, David M.
    Verhaak, Roel G.
    Heimberger, Amy B.
    Rosenthal, Mark A.
    Hovey, Elizabeth J.
    Ellingson, Benjamin M.
    Tognela, Annette
    Gan, Hui K.
    Wheeler, Helen
    Back, Michael
    Mcdonald, Kerrie L.
    Long, Anne
    Cuff, Katharine
    Begbie, Stephen
    Gedye, Craig
    Mislang, Anna
    Le, Hien
    Johnson, Margaret O.
    Kong, Benjamin Y.
    Simes, John R.
    Lwin, Zarnie
    Khasraw, Mustafa
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [46] A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study
    Kudulaiti, Nijiati
    Zhou, Zhirui
    Luo, Chen
    Zhang, Jie
    Zhu, Fengping
    Wu, Jinsong
    BMC SURGERY, 2021, 21 (01)
  • [47] Impact of Body Mass Index on Survival Outcome in Patients with Newly Diagnosed Glioblastoma: A Retrospective Single-Center Study
    Cha, Jun-Yong
    Park, Jae-Sung
    Hong, Yong-Kil
    Jeun, Sin-Soo
    Ahn, Stephen
    INTEGRATIVE CANCER THERAPIES, 2021, 20
  • [48] Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study
    Ali, Ayesha S.
    Lombardo, Joseph
    Niazi, Muneeb Z.
    Miller, Ryan C.
    Alnahhas, Iyad
    Martinez, Nina L.
    Andrews, David W.
    Judy, Kevin D.
    Shi, Wenyin
    JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (02) : 345 - 350
  • [49] Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study
    Ayesha S. Ali
    Joseph Lombardo
    Muneeb Z Niazi
    Ryan C Miller
    Iyad Alnahhas
    Nina L Martinez
    David W. Andrews
    Kevin D Judy
    Wenyin Shi
    Journal of Neuro-Oncology, 2022, 160 : 345 - 350
  • [50] Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study
    Chaskis, Elly
    Luce, Sylvie
    Goldman, Serge
    Sadeghi, Niloufar
    Melot, Christian
    De Witte, Olivier
    Devriendt, Daniel
    Lefranc, Florence
    BULLETIN DU CANCER, 2018, 105 (7-8) : 664 - 670